Pure Financial Advisors LLC Purchases New Shares in Neurocrine Biosciences, Inc. $NBIX

Pure Financial Advisors LLC bought a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the 2nd quarter, HoldingsChannel reports. The firm bought 2,696 shares of the company’s stock, valued at approximately $339,000.

Several other institutional investors have also modified their holdings of NBIX. Geneos Wealth Management Inc. grew its position in shares of Neurocrine Biosciences by 143.6% in the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after purchasing an additional 135 shares during the period. WPG Advisers LLC acquired a new stake in shares of Neurocrine Biosciences in the first quarter valued at about $32,000. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Neurocrine Biosciences in the first quarter valued at about $34,000. SVB Wealth LLC acquired a new stake in shares of Neurocrine Biosciences in the first quarter valued at about $35,000. Finally, Golden State Wealth Management LLC grew its position in shares of Neurocrine Biosciences by 116.9% in the first quarter. Golden State Wealth Management LLC now owns 397 shares of the company’s stock valued at $44,000 after purchasing an additional 214 shares during the period. Institutional investors and hedge funds own 92.59% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently issued reports on NBIX shares. Weiss Ratings reiterated a “hold (c+)” rating on shares of Neurocrine Biosciences in a research report on Saturday, September 27th. Royal Bank Of Canada lifted their target price on shares of Neurocrine Biosciences from $144.00 to $149.00 and gave the company an “outperform” rating in a research report on Friday, September 5th. Wall Street Zen raised shares of Neurocrine Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 2nd. UBS Group raised their price target on shares of Neurocrine Biosciences from $152.00 to $174.00 and gave the stock a “buy” rating in a research note on Wednesday, July 9th. Finally, Truist Financial initiated coverage on shares of Neurocrine Biosciences in a research note on Monday, July 21st. They issued a “buy” rating and a $163.00 price target on the stock. Seventeen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, Neurocrine Biosciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $161.89.

Insiders Place Their Bets

In other Neurocrine Biosciences news, insider Jude Onyia sold 59,819 shares of Neurocrine Biosciences stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $130.46, for a total transaction of $7,803,986.74. Following the transaction, the insider directly owned 18,289 shares of the company’s stock, valued at $2,385,982.94. The trade was a 76.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Ingrid Delaet sold 457 shares of the business’s stock in a transaction that occurred on Thursday, July 10th. The shares were sold at an average price of $135.00, for a total transaction of $61,695.00. Following the completion of the sale, the insider directly owned 4,730 shares in the company, valued at $638,550. This trade represents a 8.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 166,598 shares of company stock valued at $21,305,846 over the last ninety days. Company insiders own 4.80% of the company’s stock.

Neurocrine Biosciences Price Performance

Shares of NBIX stock opened at $137.03 on Friday. The firm’s 50-day moving average is $136.98 and its two-hundred day moving average is $124.19. Neurocrine Biosciences, Inc. has a 12 month low of $84.23 and a 12 month high of $154.61. The company has a market capitalization of $13.59 billion, a PE ratio of 40.54, a price-to-earnings-growth ratio of 0.99 and a beta of 0.21.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Wednesday, July 30th. The company reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $0.98 by $0.08. Neurocrine Biosciences had a net margin of 13.88% and a return on equity of 13.22%. The company had revenue of $687.50 million for the quarter, compared to the consensus estimate of $653.09 million. During the same period in the previous year, the firm earned $1.63 earnings per share. Neurocrine Biosciences’s quarterly revenue was up 16.5% compared to the same quarter last year. Sell-side analysts forecast that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current year.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.